Telomir plans Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer after preclinical publication
TELO•Combination testing with paclitaxel
Combination testing suggested stronger tumor reduction with paclitaxel in one model, while another TNBC model showed no response.
Study findings in prostate cancer and TNBC models
Studies showed tumor growth suppression in prostate cancer and TNBC models, with activity tied to an iron-dependent mechanism.
Data indicated selectivity for cancer cells over normal cells, with reduced metastatic spread in one TNBC model.
Telomir highlights preclinical publication on Telomir-Zn
Telomir Pharmaceuticals highlighted a peer-reviewed preclinical publication on Telomir-Zn, positioning it to support a planned Phase 1/2 TNBC trial.
Results have already been presented via the journal publication, not slated for a future medical meeting disclosure.
